Skip to content

The role and mechanism of transcutaneous auricular vagus nerve stimulation (taVNS) in regulating gut-brain interaction to improve neuroinflammation in depression

The role and mechanism of transcutaneous auricular vagus nerve stimulation (taVNS) in regulating gut-brain interaction to improve neuroinflammation in depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124153
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

The taVNS group:Place the stimulating electrodes on the left auricle area. Perform the intervention twice a day, each session lasting 30 minutes, for a total of 4 weeks. The stimulation parameters are
Sham taVNS group:Using the sham stimulation mode (a special driving mode, where the subject experiences a sensation similar to taVNS, but without any actual stimulation of the vagus nerve)
Control group:None

Sponsors

The First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for major depressive disorder as stipulated in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 2. First onset without medication; 3. Age ranging from 18 to 55 years old; 4. Total score of the HAMD scale (17 items) ranging from 8 to 24 points; 5. Right-handed; 6. Voluntarily participated in this study and signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Suffering from other mental disorders; 2. Having other physical diseases, especially gastrointestinal diseases; 3. Those with a severe tendency towards suicide; 4. Those with evidence of alcohol or other substance dependence or abuse; 5. Family history: Family history of mental disorders such as bipolar disorder and schizophrenia; 6. Treatment history: Have received treatment with antibiotics, probiotics, immunosuppressants, etc. within the last 1 month; 7. Reproductive history: Pregnant or lactating women; 8. Have participated in a clinical trial within the past 90 days or have participated in 2 or more clinical trials within the past year.

Design outcomes

Primary

MeasureTime frame
The decrement value and decrement rate of the HAMD17 score;

Countries

China

Contacts

Public ContactSun Ning

The First Hospital of Shanxi Medical University

sunning_sxmu@163.com+86 139 9420 4833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026